Keita Mori
Co-Founder, President, Executive Officer, CEO & Representative Director
Hello, everyone. This is Keita Mori from SanBio. Thank you, everyone, for your interest in SanBio and coming to this update meeting. Today, before I present anything, I’d like to just spend a few moments to talk about. Actually, we are extremely delighted that at the end of last year, December of 2025, we have gotten the our company first approval on our cell therapy product. This name used to be a development code SB623. Now the product name is AKUUGO has been approved in Japan for the patient who has disability — motor disability from TBI.
So this year, we will be able to start commercializing our product, AKUUGO. And this is after 25 years of rigorous efforts by everyone involved. And I’d like to also thank all the stakeholders who has been helping out and also have interest to our company. So thank you very much.
I’d like to also introduce two new executive members to our company, which is also extremely great news for us. This time, the two new executive officers will be building up or continuing to build up the one area is the production. This is Tetsuya Isono. And then another area is regulatory affairs and quality assurance, quality compliance. This is Soyoku Nobeyama. Let me introduce briefly exceptionally incredible two officers. Mr. Isono comes to SanBio with over 30 years of pharma experiences, biopharma experiences at the Chugai Pharmaceuticals. As you know, Chugai Pharmaceutical is one of the leading global biopharma companies, and they have a lot of successful biologics product such as Actemra and other products. And Mr. Isono has been instrumental in developing product
